ArticleAmerican journal of cancer research2026
Analysis of the impact of Graves' disease on the efficacy of initial radioactive iodine therapy in patients with differentiated thyroid cancer.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to assess the impact of Graves' disease (GD) on the clinicopathological characteristics and prognosis of patients with differentiated thyroid cancer (DTC) undergoing initial radioactive iodine (RAI) therapy, as well as to identify factors influencing RAI therapy outcomes. A retrospective analysis was conducted on 959 DTC patients who received initial RAI therapy at the Department of Nuclear Medicine, First Affiliated Hospital of Nanchang University, between January 2021 and December 2023. Patients were divided into two groups based on a history of GD: the GD group (n = 60) and the non-GD group (n = 899). Data on demographics, laboratory tests, clinicopathological features, and RAI-related parameters were collected. Univariate analysis was performed to identify variables associated with treatment response, followed by multivariate logistic regression to determine independent predictors of outcomes after initial RAI therapy. The distribution of treatment responses across the four categories was as follows: in the GD group, excellent response (ER) occurred in 71.67%, indeterminate response (IDR) in 16.67%, biochemical incomplete response (BIR) in 6.67%, and structural incomplete response (SIR) in 5.00%; in the non-GD group, the respective rates were 39.60% (ER), 29.37% (IDR), 17.80% (BIR), and 13.24% (SIR). Statistically significant differences were observed in dichotomous outcomes - ER versus non-excellent response (N-ER), and ideal/acceptable response versus incomplete response - between the two groups (both P < 0.01). Multivariate analysis identified several independent factors associated with favorable RAI outcomes, including younger age, GD (P < 0.001; OR = 0.16; 95% CI: 0.07-0.35), shorter interval between surgery and
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.